392 related articles for article (PubMed ID: 33275686)
1. Immunotherapy with drugs.
Choi Y; Diefenbach CS
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):598-605. PubMed ID: 33275686
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies.
Tun AM; Ansell SM
Cancer Treat Rev; 2020 Aug; 88():102042. PubMed ID: 32521386
[TBL] [Abstract][Full Text] [Related]
4. Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma.
Chu Y; Gardenswartz A; Diorio C; Marks LJ; Lowe E; Teachey DT; Cairo MS
Best Pract Res Clin Haematol; 2023 Mar; 36(1):101442. PubMed ID: 36907635
[TBL] [Abstract][Full Text] [Related]
5. Biologic agents in the management of Hodgkin lymphoma.
Rashidi A; Bartlett NL
J Natl Compr Canc Netw; 2015 May; 13(5):587-96. PubMed ID: 25964642
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in CAR T-cell therapy for lymphoma in China.
Che Y; Sun X
Clin Transl Oncol; 2023 Oct; 25(10):2793-2800. PubMed ID: 37062016
[TBL] [Abstract][Full Text] [Related]
7. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
Abramson JS; Ghosh N; Smith SM
Am Soc Clin Oncol Educ Book; 2020 May; 40():302-313. PubMed ID: 32421455
[TBL] [Abstract][Full Text] [Related]
8. Emerging new cell therapies/immune therapies in B-cell non-Hodgkin's lymphoma.
Banerjee T; Vallurupalli A
Curr Probl Cancer; 2022 Feb; 46(1):100825. PubMed ID: 35033383
[TBL] [Abstract][Full Text] [Related]
9. Immune and Cell Therapy in Non-Hodgkin Lymphoma.
Merryman RW; Houot R; Armand P; Jacobson C
Cancer J; 2020; 26(3):269-277. PubMed ID: 32496460
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma.
Hunter BD; Chen YB; Jacobson CA
Hematol Oncol Clin North Am; 2019 Aug; 33(4):687-705. PubMed ID: 31229163
[TBL] [Abstract][Full Text] [Related]
11. Current and future immunotherapeutic approaches in Hodgkin lymphoma.
Bröckelmann PJ; Borchmann P; Engert A
Leuk Lymphoma; 2016 Sep; 57(9):2014-24. PubMed ID: 27243940
[TBL] [Abstract][Full Text] [Related]
12. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.
Phillips GL; Meisenberg BR; Reece DE; Adams VR; Badros AZ; Brunner JL; Fenton RG; Filicko J; Grosso DL; Hale GA; Howard DS; Johnson VP; Kniska A; Marshall KW; Mookerjee B; Nath R; Rapoport AP; Sarkodee-Adoo C; Takebe N; Vesole DH; Wagner JL; Flomenberg N
Bone Marrow Transplant; 2004 Apr; 33(8):781-7. PubMed ID: 14767498
[TBL] [Abstract][Full Text] [Related]
13. Current Immunotherapy Approaches in Non-Hodgkin Lymphomas.
Pytlik R; Polgarova K; Karolova J; Klener P
Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33260966
[TBL] [Abstract][Full Text] [Related]
14. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
15. Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma.
Dahi PB; Moskowitz CH; Giralt SA; Lazarus HM
Expert Rev Hematol; 2019 Apr; 12(4):255-264. PubMed ID: 30874456
[TBL] [Abstract][Full Text] [Related]
16. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
17. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.
Bartlett NL; Herrera AF; Domingo-Domenech E; Mehta A; Forero-Torres A; Garcia-Sanz R; Armand P; Devata S; Izquierdo AR; Lossos IS; Reeder C; Sher T; Chen R; Schwarz SE; Alland L; Strassz A; Prier K; Choe-Juliak C; Ansell SM
Blood; 2020 Nov; 136(21):2401-2409. PubMed ID: 32730586
[TBL] [Abstract][Full Text] [Related]
18. Targeting indolent non-Hodgkin lymphoma.
Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
[TBL] [Abstract][Full Text] [Related]
19. Emerging immunotherapy in pediatric lymphoma.
Erker C; Harker-Murray P; Burke MJ
Future Oncol; 2016 Jan; 12(2):257-70. PubMed ID: 26616565
[TBL] [Abstract][Full Text] [Related]
20. Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.
Merli M; Ferrario A; Maffioli M; Arcaini L; Passamonti F
Expert Opin Investig Drugs; 2015; 24(7):897-912. PubMed ID: 25900401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
